美第奇新星生物技术宣布在Seanobi扩展性用药项目中实现患者招募里程碑，评估MN-166（Ibudilast）治疗肌萎缩侧索硬化症_老虎社区_美港股上老虎

美第奇新星生物技术宣布在Seanobi扩展性用药项目中实现患者招募里程碑，评估MN-166（Ibudilast）治疗肌萎缩侧索硬化症

美股速递07-15

美第奇新星生物技术宣布，其评估MN-166（Ibudilast）用于治疗肌萎缩侧索硬化症患者的Seanobi研究扩展性用药项目，已成功达成患者招募的关键里程碑。这一进展标志着该药物在面向特定患者群体的可及性探索方面迈出了重要一步。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohunote.com/m/news/1121081147?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-15 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121081147","market":"us","top_or_hot":-1,"title":"美第奇新星生物技术宣布在Seanobi扩展性用药项目中实现患者招募里程碑，评估MN-166（Ibudilast）治疗肌萎缩侧索硬化症","media":"美股速递","content":"<p>美第奇新星生物技术宣布，其评估MN-166（Ibudilast）用于治疗肌萎缩侧索硬化症患者的Seanobi研究扩展性用药项目，已成功达成患者招募的关键里程碑。这一进展标志着该药物在面向特定患者群体的可及性探索方面迈出了重要一步。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美第奇新星生物技术宣布在Seanobi扩展性用药项目中实现患者招募里程碑，评估MN-166（Ibudilast）治疗肌萎缩侧索硬化症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美第奇新星生物技术宣布在Seanobi扩展性用药项目中实现患者招募里程碑，评估MN-166（Ibudilast）治疗肌萎缩侧索硬化症\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-07-15 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>美第奇新星生物技术宣布，其评估MN-166（Ibudilast）用于治疗肌萎缩侧索硬化症患者的Seanobi研究扩展性用药项目，已成功达成患者招募的关键里程碑。这一进展标志着该药物在面向特定患者群体的可及性探索方面迈出了重要一步。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNOV","symbol_name":"美第奇新星生物技术","start_time":0,"source_url":"","article_id":"1121081147","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121081147","pubTimestamp":1784117008,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"美第奇新星生物技术宣布，其评估MN-166（Ibudilast）用于治疗肌萎缩侧索硬化症患者的Seanobi研究扩展性用药项目，已成功达成患者招募的关键里程碑。这一进展标志着该药物在面向特定患者群体的可及性探索方面迈出了重要一步。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"MNOV":"美第奇新星生物技术","BK4139":"生物科技"},"translate_title":"Medici Nova Biotech Announces Patient Recruitment Milestone in Seanobi Extended Medication Program to Evaluate MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNOV":1},"content_text":"美第奇新星生物技术宣布，其评估MN-166（Ibudilast）用于治疗肌萎缩侧索硬化症患者的Seanobi研究扩展性用药项目，已成功达成患者招募的关键里程碑。这一进展标志着该药物在面向特定患者群体的可及性探索方面迈出了重要一步。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}